Toxic Epidermal Neurolysis Market – Demand, Growth & Forecast 2023-2033

Toxic Epidermal Neurolysis Market Snapshot (2023 to 2033)

The global toxic epidermal neurolysis market was anticipated to reach a valuation of USD 8.61 Billion in the year 2022. With a steady CAGR of 4.1% from 2023 to 2033, this market is expected to reach USD 8.97 Billion by 2023 and USD 13.4 Billion by 2033.

Toxic epidermal neurolysis, or TEN syndromes, are rare, severe forms of Stevens-Johnson syndrome (SJS). SJS only causes skin to blister and peel on roughly 10% of the body. When between 10% and 30% of the body is covered, both situations exist. Every year, SJS, as well as TEN, together impact between 1 and 2 million people. Such factors are expected to propel the market growth during the forecast period.

Apart from these, certain kinds of drugs trigger this condition among patients. Some of those drugs are:

• The medication allopurinol is used to treat gout as well as kidney stones.
• Antiretroviral medications for the treatment of HIV, particularly NNRTIs like efavirenz, nevirapine, or etravirine.
• Anticonvulsants are a class of medications used to treat epilepsy.
• One example of an antibiotic is sulfonamides.
• Oxicams are a class of NSAIDs or non-steroidal anti-inflammatory medications.

The clinical sign of TEN is a significant skin separation brought on by severe keratinocyte cell loss coupled with mucosal involvement. It's unclear what exactly causes TEN to be pathogenic. Many elements that may help induce keratinocyte apoptosis have been identified as a consequence of recent advancements in this research. Additionally, it appears that certain medicines and the emergence of TEN are associated with particular human leukocyte antigen subtypes. Such extensive research in this domain can spur the demand in the global toxic epidermal neurolysis market from 2023 to 2033.

The usage of this procedure along with the usage of various antibiotics is expected to open up new opportunities in this market globally. Once the afflicted skin has re-epithelialized, supportive care is the main therapy for TEN. Instances of supportive interventions include fluid resuscitation, pain treatment, wound care, as well as nutritional assistance. Abolishment of the offending medicine and prompt referral to a burn unit or critical care unit having experience in handling such cases should be the emergency department's top priorities in these situations. When applied during the first 24 hours of blistering development, these two steps decrease infection rates, and length of hospital stays, and increase overall survival. Hence, this procedure has got a high chance of success for burn patients.

Over the projected period, antibiotics are anticipated to have a sizable impact on the growth of the marketplace for toxic epidermal neurolysis. Most patients with toxic epidermal neurolysis receive prescriptions for antibiotics to treat or prevent infections. On the opposite hand, immunoglobulins are anticipated to provide a substantial contribution to market expansion for toxic epidermal neurolysis throughout the projected timeframe.

Several key players are focused on developing new products to enhance the overall efficacy of neurolysis. For instance, the FDA approved NeuromarkTM Rhinitis Neurolysis TherapyTM (RNT) in 2021, giving doctors access to an in-office procedure that interrupts the rear nasal nerves among patients with persistent rhinitis by creating lesions. Using a flexible electrode array shape, NeuromarkTM RNT may access and damage difficult-to-reach rear nasal nerves in a single insertion. Moreover, this device employs sophisticated algorithmic controls that provide the doctor the ability to safely and comfortably disrupt many nerve branches at the same time with excellent anatomical accuracy.

Data Point	Key Statistics
Expected Market value in 2023	USD 8.97 Billion
Expected Market value in 2033	USD 13.4 Billion
Growth Rate (2023 to 2033)	4.1%

Toxic epidermal necrolysis (TEN) is a potentially life-threatening dermatologic disorder characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis and/or death.

Mucous membrane involvement can result in gastrointestinal hemorrhage, respiratory failure, ocular abnormalities, and genitourinary complications. Based on drug class, the toxic epidermal market can be segmented into antibiotics, corticosteroids and immunoglobulins.

The antibiotic segment is expected to contribute considerable growth during the forecast period. The severity of toxic epidermal neurolysis is expected to contribute towards the market growth , although the disease is rare and has a lower frequency globally.

The outbreak of COVID-19 has appeared to have affected the toxic epidermal neurolysis market. The breakout of this disease has led to lockdowns across globe which has slowed down the growth in this market. However, the market is expected to catch up and grow significantly in the forecast years.

Toxic Epidermal Neurolysis Market: Drivers and Restraints

To help in building preventive strategies, the move towards advanced non-invasive approaches for early diagnosis of toxic epidermal neurolysis is expected to boost the growth of the global toxic epidermal neurolysis market. The growing consciousness about aesthetics may also contribute towards the growth of toxic epidermal neurolysis market. However, the low frequency of the disease may restrain the growth of toxic epidermal neurolysis market.

Toxic Epidermal Neurolysis Market: Overview

The global market for toxic epidermal neurolysis market is estimated to experience a significant growth due to the increasing demand for early diagnosis of the disease. Based on type, the global toxic epidermal neurolysis market is segmented into brain antibiotics, corticosteroids and immunoglobulins.

Antibiotics are expected to contribute considerable growth during the forecast period in the toxic epidermal neurolysis market. As antibiotics are prescribed to majority of the patients with toxic epidermal neurolysis to prevent or treat any infections. However, immunoglobulins are also expected to contribute significant growth in the toxic epidermal neurolysis market during the forecast period.

Based on components the toxic epidermal neurolysis market may be divided into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies and retail pharmacies are expected to contribute the largest portion of revenue in the forecast years. However, with the rapid changes in technology and growing acceptance of e-commerce by the people worldwide, it may lead to the growth of the online pharmacies in the forecast years.

Toxic Epidermal Neurolysis Market: Regional-Wise Outlook

Geographically, the toxic epidermal neurolysis market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa. The North America is expected to account for the largest share in the toxic epidermal neurolysis market due to incidence of the disease which is highest in this region.

Europe is expected to have the largest share due to improving medical infrastructure. However, East Asia is expected to observe a substantial growth in the toxic epidermal neurolysis market due to growing consciousness for aesthetics. On the other hand, South Asia is anticipated to experience fastest growth in the toxic epidermal neurolysis market as a result of developing medical infrastructure.

In the Middle East and Africa the market is expected to experience limited due to slow economic growth, underdeveloped infrastructure and lower access to technological advancement.

Toxic Epidermal Neurolysis Market: Key players

Some of the players identified in the toxic epidermal neurolysis market include:

• Pfizer
• Novartis
• Sanofi
• Merck and Co
• Sun pharma
• Abbott laboratories
• Johnson & Johnson
• Teva pharmaceuticals
• Mylan pharmaceuticals

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology Matrix
• Value Chain

Regional analysis of the toxic epidermal neurolysis market report includes

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Table of Content

• 1. Executive Summary
• 2. Industry Introduction, including Taxonomy and Market Definition
• 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
• 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
• 5. Pricing Analysis
• 6. Global Market Analysis and Forecast
  • 6.1. Drug Class
  • 6.2. Distribution Channel
• 7. Global Market Analysis and Forecast, By Drug Class
  • 7.1. Antibiotics
  • 7.2. Corticosteroids
  • 7.3. Intravenous immunoglobulins
• 8. Global Market Analysis and Forecast, By Distribution Channel
  • 8.1. Hospital pharmacies
  • 8.2. Retail pharmacies
  • 8.3. Online pharmacies
• 9. Global Market Analysis and Forecast, By Region
  • 9.1. North America
  • 9.2. Latin America
  • 9.3. Europe
  • 9.4. South Asia
  • 9.5. East Asia
  • 9.6. Oceania
  • 9.7. Middle East and Africa
• 10. North America Sales Analysis and Forecast, by Key Segments and Countries
• 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries
• 12. Europe Sales Analysis and Forecast, by Key Segments and Countries
• 13. South Asia Sales Analysis and Forecast, by Key Segments and Countries
• 14. East Asia Sales Analysis and Forecast, by Key Segments and Countries
• 15. Oceania Sales Analysis and Forecast, by Key Segments and Countries
• 16. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries
• 17. Sales Forecast by Drug Class and Distribution Channel for 30 Countries
• 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
• 19. Company Profile
  • 19.1. Pfizer
  • 19.2. Novartis
  • 19.3. Sanofi
  • 19.4. Merck and Co
  • 19.5. Sun Pharma
  • 19.6. Abbott Laboratories
  • 19.7. Johnson & Johnson
  • 19.8. Teva Pharmaceuticals
  • 19.9. Mylan Pharmaceuticals